Genelux Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNLX research report →
Range $16 – $20
Price Chart
About the company
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers.
- CEO
- Thomas D. Zindrick
- IPO
- 2023
- Employees
- 26
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on GNLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $122.86M
- P/E
- -3.08
- Fwd P/E
- 3.83
- PEG
- 1.30
- P/S
- 15357.84
- P/B
- 7.65
- EV/EBITDA
- -3.40
- Div Yield
- 0.00%
- Gross Margin
- -1762.50%
- Op Margin
- -445200.00%
- Net Margin
- -422412.50%
- ROE
- -195.42%
- ROIC
- -192.18%
Latest fiscal year · YoY change
- Revenue
- $8.00K+0.0%
- Gross Profit
- $-566,000+36.8%
- Op Income
- $-33,214,000
- Net Income
- $-32,145,000-7.6%
- EPS
- $-0.86+9.5%
- OCF Growth
- -19.0%
- FCF Growth
- -22.0%
- 52W High
- $8.54
- 52W Low
- $2.29
- 50D MA
- $2.87
- 200D MA
- $3.28
- Beta
- 0.59
- RSI (14)
- 48
- Avg Volume
- 219.06K
No earnings-call transcripts are available for GNLX yet.
- Free Float
- 80.6%
- Shares Outstanding
- 44.84M
- Float Shares
- 36.13M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.55M | ▲ 132.07K |
| Centaurus Financial, Inc. | 10.00K | 0 |
Held by 21 ETFs
Biggest fund positions in GNLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 26 | Yu Yong | sell | 653 |
| Aug 4, 26 | Cappello Joseph | sell | 653 |
| Aug 4, 26 | Zindrick Thomas | sell | 3,023 |
| Jul 1, 26 | Smither John W | sell | 12,000 |
| Jun 16, 26 | Pulisic Matthew | other | 278,906 |
| Jun 16, 26 | Groen Eric | other | 233,957 |
| Jun 16, 26 | Cappello Joseph | other | 174,841 |
| Jun 16, 26 | Tyree James L | other | 28,409 |
| Jun 16, 26 | Tyree James L | other | 31,566 |
| Jun 16, 26 | Zindrick Thomas | other | 730,601 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GNLX coverage
Recent articles, reports, and earnings notes.
No research on GNLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNLX report →Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
globenewswire.com · Aug 13
Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday
defenseworld.net · Aug 5
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
globenewswire.com · Jun 30
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
globenewswire.com · May 7
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
globenewswire.com · Mar 19
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
globenewswire.com · Jan 12
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
globenewswire.com · Jan 8
Genelux Corporation Announces Proposed Public Offering of Common Stock
globenewswire.com · Jan 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.